Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

Summary

This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC699 that can be given safely to participants * Evaluate the safety profile of AC699 * Evaluate the pharmacokinetics of AC699 * Evaluate the effectiveness of AC699

Timeline

Start

2022-12-29

Primary completion

2026-03-31

Completion

2026-05-31

Publications

• Hamilton E, Layman RM, Cosgrove D, Danso M, Zhang H, He W, Kim SY, Fan J, Patel MR. ER degradation for ER+/HER2- advanced or metastatic breast cancer: a phase 1 trial. Nat Commun. 2025 Dec 17;17(1):796. doi: 10.1038/s41467-025-67485-y.

Drugs

Indications